Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 184 of 6351
-
Can flickering light and pulsed sound shield new mothers from postpartum depression?
Prevention Not yet recruitingPostpartum depression (PPD) is a common mental health condition affecting 10%-30% of new mothers, with serious consequences for both mother and child. Effective prevention is limited by barriers to psychological or pharmacological treatments. This study evaluates whether short-t…
Sponsor: The First People's Hospital of Lianyungang • Aim: Prevention
Last updated Sep 10, 2026 00:00 UTC
-
Zapping the brain to steady Parkinson's steps?
Disease control Not yet recruitingThis study will compare different treatment schedules of combined transcranial direct current stimulation (tDCS) and transcranial ultrasound stimulation (TUS) in participants with Parkinson's disease. Participants will be randomly assigned to one of four groups: Standard (10 sess…
Sponsor: Felipe Fregni, MD, PhD, MPH • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a blood filter tame the inflammatory storm after pediatric heart surgery?
Disease control Not yet recruitingThe Localized Evidence of Cytokine Adsorption Therapy (LEAT) study is a prospective, randomized controlled trial conducted at the Institut Jantung Negara in Malaysia. It evaluates the efficacy and safety of using Jafron HA-60 and HA380 hemoadsorption cartridges to reduce systemic…
Sponsor: Norfaniza Zabidi • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a simple rinse reveal ovarian Cancer's earliest signs?
Diagnosis Not yet recruitingThis clinical trial develops a non-surgical approach using uterine lavage samples to screen for progression to ovarian cancer in high-risk patients carrying BRCA mutations. Women with inherited mutations in the BRCA1 and BRCA2 genes (BRCA carriers) have a much higher lifetime ris…
Sponsor: University of Washington • Aim: Diagnosis
Last updated Sep 10, 2026 00:00 UTC
-
Mind-Controlled rehab: could brain signals restore hand movement after stroke?
Disease control Not yet recruitingStroke is a leading cause of long-term disability, with 30-60% of survivors remaining unable to use their affected arms after discharge. Existing rehabilitation approaches such as motor imagery, robotic assistance, and neuromodulation have shown limited effectiveness for hand mot…
Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can an mRNA injection rebuild lymphatic flow and ease arm swelling?
Disease control Not yet recruitingLymphedema is a common complication of breast cancer treatment, affecting approximately a quarter of patients. Those affected can have an uncomfortable, unsightly and sometimes functionally impaired limb prone to episodes of superficial infection. The aetiology and pathophysiolog…
Phase 1/2 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Which drug tames liver Graft-Versus-Host disease better? a trial puts two to the test
Disease control Recruiting nowThis prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT. Ruxolitinib and belumosudil are both effective for cGVHD, but no head-to-head comparison specifically in hepatic cGVHD has been reported…
Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a drug duo outsmart resistant lung cancer?
Disease control Not yet recruitingThis study is a single arm study to access the anti-tumor efficacy and safety of Andamertinib plus Anlotinib in patients with locally advanced or metastatic non-small cell lung cancer previously treated with third-generation EGFR-TKI.
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new pill slow Parkinson's motor decline?
Disease control Not yet recruitingThe purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of RO7568282 compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a migraine drug ease endometriosis pain?
Symptom relief Not yet recruitingThe purpose of this study is to evaluate the efficacy of rimegepant 75 mg versus placebo in reducing endometriosis-associated pain (EAP) in women with moderate-to-severe pain and histologically confirmed endometriosis.
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Can the choice of anesthesia shield the aging brain after tumor surgery?
Disease control Not yet recruitingThis study will compare three anesthesia medicines used to put people into a deep sleep during surgery: ciprofol, propofol, and sevoflurane. All three are commonly used for general anesthesia, but they work in different ways. Ciprofol and propofol are given through a vein. Sevofl…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can your own fat help heal diabetic wounds?
Disease control Not yet recruitingThis is a randomized controlled multi center study on diabetic patients with the aim of evaluating the efficacy of the adipose tissue processed with the SyntrFuge™ system in diabetic patients with diabetic foot ulcers. In particular, it will be evaluated whether the microsized fa…
Sponsor: Syntr Health Technologies, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can adding a hormone pill to chemotherapy shrink breast tumors better before surgery?
Disease control Not yet recruitingThe goal of this investigator-initiated, open-label, phase II clinical trial is to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, Ki…
Phase 2 • Sponsor: The Second Hospital of Anhui Medical University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a smart drug hunt down sarcoma cells without harming healthy ones?
Disease control Not yet recruitingSOT106 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called LRRC15, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT106, understan…
Phase 1/2 • Sponsor: SOTIO Biotech a.s. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can stronger cholesterol drugs silence the threat of stroke?
Prevention Not yet recruitingIt is designed to compare two different strengths of cholesterol-lowering treatment in patients who have narrowing of blood vessels inside the brain (intracranial atherosclerosis) but do not currently have symptoms such as stroke. The purpose of this study is to find out whether…
Sponsor: Woo-Keun Seo • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
Can a primer drug make chemotherapy work better for frail head and neck cancer patients?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the drug Toripalimab can prime the tumor to optimize response to Paclitaxel in HNSCC patients with a decrease performance status in a way that make both drugs well tolerated and improve partial or complete response rate over each tre…
Phase 2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new injection slow kidney disease in children?
Disease control Not yet recruitingThis Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric participants aged 2 to 17 years with IgA nephropathy (IgAN). S…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310. The purpose of Part 2 is to see how obrixtamig and…
Phase 1/2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can adding lurasidone to antidepressants lift depression that Won't budge?
Disease control Not yet recruitingThis Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of lurasidone as adjunctive therapy in adult patients with major depressive disorder (MDD) who show an inadequate response to antidepressant mono…
Phase 3 • Sponsor: Bukwang Pharmaceutical • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new biologic calm severe eczema?
Disease control Not yet recruitingThis is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female. It will also learn about the safety of drug Nemolizumab. Researchers will compare drug N…
Phase 3 • Sponsor: Galderma R&D • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC